Mechanistic Physiologically Based Pharmacokinetic (PBPK) Model of the Heart Accounting for Inter-Individual Variability: Development and Performance Verification

Modern model-based approaches to cardiac safety and efficacy assessment require accurate drug concentration-effect relationship establishment. Thus, knowledge of the active concentration of drugs in heart tissue is desirable along with inter-subject variability influence estimation. To that end, we...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of pharmaceutical sciences 2018-04, Vol.107 (4), p.1167-1177
Hauptverfasser: Tylutki, Zofia, Mendyk, Aleksander, Polak, Sebastian
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1177
container_issue 4
container_start_page 1167
container_title Journal of pharmaceutical sciences
container_volume 107
creator Tylutki, Zofia
Mendyk, Aleksander
Polak, Sebastian
description Modern model-based approaches to cardiac safety and efficacy assessment require accurate drug concentration-effect relationship establishment. Thus, knowledge of the active concentration of drugs in heart tissue is desirable along with inter-subject variability influence estimation. To that end, we developed a mechanistic physiologically based pharmacokinetic model of the heart. The models were described with literature-derived parameters and written in R, v.3.4.0. Five parameters were estimated. The model was fitted to amitriptyline and nortriptyline concentrations after an intravenous infusion of amitriptyline. The cardiac model consisted of 5 compartments representing the pericardial fluid, heart extracellular water, and epicardial intracellular, midmyocardial intracellular, and endocardial intracellular fluids. Drug cardiac metabolism, passive diffusion, active efflux, and uptake were included in the model as mechanisms involved in the drug disposition within the heart. The model accounted for inter-individual variability. The estimates of optimized parameters were within physiological ranges. The model performance was verified by simulating 5 clinical studies of amitriptyline intravenous infusion, and the simulated pharmacokinetic profiles agreed with clinical data. The results support the model feasibility. The proposed structure can be tested with the goal of improving the patient-specific model-based cardiac safety assessment and offers a framework for predicting cardiac concentrations of various xenobiotics.
doi_str_mv 10.1016/j.xphs.2017.11.012
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1969931360</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0022354917308341</els_id><sourcerecordid>1969931360</sourcerecordid><originalsourceid>FETCH-LOGICAL-c356t-a82792aa1656e80d270cb3c5b7a01b4cc4201f125dd79fc104429284f5527903</originalsourceid><addsrcrecordid>eNp9kcFu1DAURS0EokPhB1ggL8siwXbiZILYtIXSEa2YRdWt5dgvHQ-OPbWdEfM5_GkdTWHJytLTudf2Owi9p6SkhDaftuXv3SaWjNC2pLQklL1AC8oZKZo8eokWhDBWVLzuTtCbGLeEkIZw_hqdsI62vKZ0gf7cgtpIZ2IyCq83h2i89Q9GSWsP-EJG0HkqwyiV_2UczNTZ-mL94yO-9Ros9gNOG8DXIEPC50r5ySXjHvDgA165BKFYOW32Rk_S4nsZjOyNNenwGX-FPVi_G8ElLF2-BkIOjdIpwPcQzJAfkYx3b9GrQdoI757PU3R39e3u8rq4-fl9dXl-U6iKN6mQS9Z2TEra8AaWRLOWqL5SvG8loX2tVJ33NFDGtW67QVFS16xjy3rgPAdJdYrOjrW74B8niEmMJiqwVjrwUxS0a7quolUzo-yIquBjDDCIXTCjDAdBiZjNiK2YzYjZjKBUZDM59OG5f-pH0P8if1Vk4MsRgPzJvYEgojKQt6FNAJWE9uZ__U9OFqFR</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1969931360</pqid></control><display><type>article</type><title>Mechanistic Physiologically Based Pharmacokinetic (PBPK) Model of the Heart Accounting for Inter-Individual Variability: Development and Performance Verification</title><source>Alma/SFX Local Collection</source><creator>Tylutki, Zofia ; Mendyk, Aleksander ; Polak, Sebastian</creator><creatorcontrib>Tylutki, Zofia ; Mendyk, Aleksander ; Polak, Sebastian</creatorcontrib><description>Modern model-based approaches to cardiac safety and efficacy assessment require accurate drug concentration-effect relationship establishment. Thus, knowledge of the active concentration of drugs in heart tissue is desirable along with inter-subject variability influence estimation. To that end, we developed a mechanistic physiologically based pharmacokinetic model of the heart. The models were described with literature-derived parameters and written in R, v.3.4.0. Five parameters were estimated. The model was fitted to amitriptyline and nortriptyline concentrations after an intravenous infusion of amitriptyline. The cardiac model consisted of 5 compartments representing the pericardial fluid, heart extracellular water, and epicardial intracellular, midmyocardial intracellular, and endocardial intracellular fluids. Drug cardiac metabolism, passive diffusion, active efflux, and uptake were included in the model as mechanisms involved in the drug disposition within the heart. The model accounted for inter-individual variability. The estimates of optimized parameters were within physiological ranges. The model performance was verified by simulating 5 clinical studies of amitriptyline intravenous infusion, and the simulated pharmacokinetic profiles agreed with clinical data. The results support the model feasibility. The proposed structure can be tested with the goal of improving the patient-specific model-based cardiac safety assessment and offers a framework for predicting cardiac concentrations of various xenobiotics.</description><identifier>ISSN: 0022-3549</identifier><identifier>EISSN: 1520-6017</identifier><identifier>DOI: 10.1016/j.xphs.2017.11.012</identifier><identifier>PMID: 29175411</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>disposition ; in silico modeling ; pharmacokinetic/pharmacodynamic models ; pharmacokinetics ; physiological model</subject><ispartof>Journal of pharmaceutical sciences, 2018-04, Vol.107 (4), p.1167-1177</ispartof><rights>2018 American Pharmacists Association</rights><rights>Copyright © 2018 American Pharmacists Association®. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c356t-a82792aa1656e80d270cb3c5b7a01b4cc4201f125dd79fc104429284f5527903</citedby><cites>FETCH-LOGICAL-c356t-a82792aa1656e80d270cb3c5b7a01b4cc4201f125dd79fc104429284f5527903</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29175411$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tylutki, Zofia</creatorcontrib><creatorcontrib>Mendyk, Aleksander</creatorcontrib><creatorcontrib>Polak, Sebastian</creatorcontrib><title>Mechanistic Physiologically Based Pharmacokinetic (PBPK) Model of the Heart Accounting for Inter-Individual Variability: Development and Performance Verification</title><title>Journal of pharmaceutical sciences</title><addtitle>J Pharm Sci</addtitle><description>Modern model-based approaches to cardiac safety and efficacy assessment require accurate drug concentration-effect relationship establishment. Thus, knowledge of the active concentration of drugs in heart tissue is desirable along with inter-subject variability influence estimation. To that end, we developed a mechanistic physiologically based pharmacokinetic model of the heart. The models were described with literature-derived parameters and written in R, v.3.4.0. Five parameters were estimated. The model was fitted to amitriptyline and nortriptyline concentrations after an intravenous infusion of amitriptyline. The cardiac model consisted of 5 compartments representing the pericardial fluid, heart extracellular water, and epicardial intracellular, midmyocardial intracellular, and endocardial intracellular fluids. Drug cardiac metabolism, passive diffusion, active efflux, and uptake were included in the model as mechanisms involved in the drug disposition within the heart. The model accounted for inter-individual variability. The estimates of optimized parameters were within physiological ranges. The model performance was verified by simulating 5 clinical studies of amitriptyline intravenous infusion, and the simulated pharmacokinetic profiles agreed with clinical data. The results support the model feasibility. The proposed structure can be tested with the goal of improving the patient-specific model-based cardiac safety assessment and offers a framework for predicting cardiac concentrations of various xenobiotics.</description><subject>disposition</subject><subject>in silico modeling</subject><subject>pharmacokinetic/pharmacodynamic models</subject><subject>pharmacokinetics</subject><subject>physiological model</subject><issn>0022-3549</issn><issn>1520-6017</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp9kcFu1DAURS0EokPhB1ggL8siwXbiZILYtIXSEa2YRdWt5dgvHQ-OPbWdEfM5_GkdTWHJytLTudf2Owi9p6SkhDaftuXv3SaWjNC2pLQklL1AC8oZKZo8eokWhDBWVLzuTtCbGLeEkIZw_hqdsI62vKZ0gf7cgtpIZ2IyCq83h2i89Q9GSWsP-EJG0HkqwyiV_2UczNTZ-mL94yO-9Ros9gNOG8DXIEPC50r5ySXjHvDgA165BKFYOW32Rk_S4nsZjOyNNenwGX-FPVi_G8ElLF2-BkIOjdIpwPcQzJAfkYx3b9GrQdoI757PU3R39e3u8rq4-fl9dXl-U6iKN6mQS9Z2TEra8AaWRLOWqL5SvG8loX2tVJ33NFDGtW67QVFS16xjy3rgPAdJdYrOjrW74B8niEmMJiqwVjrwUxS0a7quolUzo-yIquBjDDCIXTCjDAdBiZjNiK2YzYjZjKBUZDM59OG5f-pH0P8if1Vk4MsRgPzJvYEgojKQt6FNAJWE9uZ__U9OFqFR</recordid><startdate>201804</startdate><enddate>201804</enddate><creator>Tylutki, Zofia</creator><creator>Mendyk, Aleksander</creator><creator>Polak, Sebastian</creator><general>Elsevier Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201804</creationdate><title>Mechanistic Physiologically Based Pharmacokinetic (PBPK) Model of the Heart Accounting for Inter-Individual Variability: Development and Performance Verification</title><author>Tylutki, Zofia ; Mendyk, Aleksander ; Polak, Sebastian</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c356t-a82792aa1656e80d270cb3c5b7a01b4cc4201f125dd79fc104429284f5527903</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>disposition</topic><topic>in silico modeling</topic><topic>pharmacokinetic/pharmacodynamic models</topic><topic>pharmacokinetics</topic><topic>physiological model</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tylutki, Zofia</creatorcontrib><creatorcontrib>Mendyk, Aleksander</creatorcontrib><creatorcontrib>Polak, Sebastian</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of pharmaceutical sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tylutki, Zofia</au><au>Mendyk, Aleksander</au><au>Polak, Sebastian</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Mechanistic Physiologically Based Pharmacokinetic (PBPK) Model of the Heart Accounting for Inter-Individual Variability: Development and Performance Verification</atitle><jtitle>Journal of pharmaceutical sciences</jtitle><addtitle>J Pharm Sci</addtitle><date>2018-04</date><risdate>2018</risdate><volume>107</volume><issue>4</issue><spage>1167</spage><epage>1177</epage><pages>1167-1177</pages><issn>0022-3549</issn><eissn>1520-6017</eissn><abstract>Modern model-based approaches to cardiac safety and efficacy assessment require accurate drug concentration-effect relationship establishment. Thus, knowledge of the active concentration of drugs in heart tissue is desirable along with inter-subject variability influence estimation. To that end, we developed a mechanistic physiologically based pharmacokinetic model of the heart. The models were described with literature-derived parameters and written in R, v.3.4.0. Five parameters were estimated. The model was fitted to amitriptyline and nortriptyline concentrations after an intravenous infusion of amitriptyline. The cardiac model consisted of 5 compartments representing the pericardial fluid, heart extracellular water, and epicardial intracellular, midmyocardial intracellular, and endocardial intracellular fluids. Drug cardiac metabolism, passive diffusion, active efflux, and uptake were included in the model as mechanisms involved in the drug disposition within the heart. The model accounted for inter-individual variability. The estimates of optimized parameters were within physiological ranges. The model performance was verified by simulating 5 clinical studies of amitriptyline intravenous infusion, and the simulated pharmacokinetic profiles agreed with clinical data. The results support the model feasibility. The proposed structure can be tested with the goal of improving the patient-specific model-based cardiac safety assessment and offers a framework for predicting cardiac concentrations of various xenobiotics.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>29175411</pmid><doi>10.1016/j.xphs.2017.11.012</doi><tpages>11</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0022-3549
ispartof Journal of pharmaceutical sciences, 2018-04, Vol.107 (4), p.1167-1177
issn 0022-3549
1520-6017
language eng
recordid cdi_proquest_miscellaneous_1969931360
source Alma/SFX Local Collection
subjects disposition
in silico modeling
pharmacokinetic/pharmacodynamic models
pharmacokinetics
physiological model
title Mechanistic Physiologically Based Pharmacokinetic (PBPK) Model of the Heart Accounting for Inter-Individual Variability: Development and Performance Verification
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-11T03%3A27%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Mechanistic%20Physiologically%20Based%20Pharmacokinetic%20(PBPK)%20Model%20of%20the%20Heart%20Accounting%20for%20Inter-Individual%20Variability:%20Development%20and%20Performance%20Verification&rft.jtitle=Journal%20of%20pharmaceutical%20sciences&rft.au=Tylutki,%20Zofia&rft.date=2018-04&rft.volume=107&rft.issue=4&rft.spage=1167&rft.epage=1177&rft.pages=1167-1177&rft.issn=0022-3549&rft.eissn=1520-6017&rft_id=info:doi/10.1016/j.xphs.2017.11.012&rft_dat=%3Cproquest_cross%3E1969931360%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1969931360&rft_id=info:pmid/29175411&rft_els_id=S0022354917308341&rfr_iscdi=true